In a report released on November 3, Prasath Pandurangan from Bloom Burton maintained a Buy rating on Aurinia Pharmaceuticals (AUPH – Research Report), with a price target of $10.50. The company’s shares closed last Friday at $5.15.
According to TipRanks, Pandurangan is an analyst with an average return of -17.5% and a 26.42% success rate.
Currently, the analyst consensus on Aurinia Pharmaceuticals is a Strong Buy with an average price target of $11.63, implying a 125.83% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $14.00 price target.
Based on Aurinia Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $28.19 million and a GAAP net loss of $35.52 million. In comparison, last year the company earned a revenue of $6.62 million and had a GAAP net loss of $47.01 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
Read More on AUPH:
- Aurinia Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
- Aurinia Tanks Upon Low Patient Uptake for Lupkynis and Reduced Outlook
- Aurinia Pharmaceuticals lowers FY22 revenue view to $100M-105M from $115M-$135M
- Aurinia Pharmaceuticals reports Q3 EPS (6c), consensus (17c)
- Biotech Alert: Searches spiking for these stocks today